cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytosorbents Corp
7 own
10 watching
Current Price
$4.17
$0.61
(17.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
181.96M
52-Week High
52-Week High
4.59
52-Week Low
52-Week Low
1.03
Average Volume
Average Volume
0.53M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization181.96M
icon52-Week High4.59
icon52-Week Low1.03
iconAverage Volume0.53M
iconDividend Yield--
iconP/E Ratio--
What does the Cytosorbents Corp do?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Read More
How much money does Cytosorbents Corp make?
News & Events about Cytosorbents Corp.
Ticker Report
9days ago
StockNews.com lowered shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a hold rating to a sell rating in a research note released on Thursday. Separately, HC Wainwright decreased their target price on Cytosorbents from $9.00 to $5.50 and set a buy rating for the company in a research ...
Ticker Report
1month ago
StockNews.com upgraded shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a sell rating to a hold rating in a research report report published on Thursday morning. Separately, HC Wainwright cut their price objective on Cytosorbents from $9.00 to $5.50 and set a buy rating on the stock in a...
Benzinga
1month ago
Cytosorbents Corp (NASDAQ: CTSO)shares are trading higher by 15.55% to $1.38 Thursday afternoon after the company announced it received $5 million in non-dilutive debt financing from Bridge Bank and extended a loan agreement. What's Happening? read more...
PR Newswire
1month ago
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement PR Newswire PRINCETON, N.J., Dec. 29, 2022 Non-dilutive debt capital at market favorable terms...
PR Newswire
1month ago
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without...
Frequently Asked Questions
Frequently Asked Questions
What is Cytosorbents Corp share price today?
plus_minus_icon
Can Indians buy Cytosorbents Corp shares?
plus_minus_icon
How can I buy Cytosorbents Corp shares from India?
plus_minus_icon
Can Fractional shares of Cytosorbents Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cytosorbents Corp stocks?
plus_minus_icon
What is today’s traded volume of Cytosorbents Corp?
plus_minus_icon
What is today’s market capitalisation of Cytosorbents Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cytosorbents Corp?
plus_minus_icon
What percentage is Cytosorbents Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cytosorbents Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$4.17
$0.61
(17.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00